2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $17M | -$10M | 20.5% | -60.6% | $2M | $11M | $7M |
| 2024 | $26M | $2M | 49.0% | 8.8% | $4M | $12M | $3M |
How the market has priced ZYBT against its own fundamentals since 2025-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 1 years, Zhengye Biotechnology Holding Ltd's revenue has declined 34.8% per year. These are computed facts, not advice.
As of FY2025, Zhengye Biotechnology Holding Ltd reported $11M of total debt against $7M of cash; operating income covered interest expense -20.7×.
In FY2025, gross margin was 20.5%, operating margin -60.6%, and net margin -60.0%.
As of Jun '26, Zhengye Biotechnology Holding Ltd traded at a price-to-earnings ratio of about 64.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.